MarketJanus kinase 2
Company Profile

Janus kinase 2

Janus kinase 2 is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family, the GM-CSF receptor family, the gp130 receptor family, and the single chain receptors.

Clinical significance
JAK2 gene fusions with the TEL(ETV6) (TEL-JAK2) and PCM1 genes have been found in patients suffering leukemia, particularly clonal eosinophilia forms of the disease. Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, and myelofibrosis as well as other myeloproliferative disorders. This mutation (V617F), a change of valine to phenylalanine at the 617 position, appears to render hematopoietic cells more sensitive to growth factors such as erythropoietin and thrombopoietin, because the receptors for these growth factors require JAK2 for signal transduction. JAK2 mutation, when demonstrable, is one of the methods of diagnosing polycythemia vera. == Interactions ==
Interactions
Janus kinase 2 has been shown to interact with: • DNAJA3EGFREPORFYNGrb2GHRIRS1IL12RB2IL5RAPIK3R1PPP2R4PTPN11PTPN6PRMT5SH2B1SHC1SOCS3STAT5ASTAT5BSOCS1TECTNFRSF1AVAV1YES1 == See also ==
tickerdossier.comtickerdossier.substack.com